nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP2C18—Dapsone—systemic lupus erythematosus	0.0788	0.114	CbGbCtD
Lansoprazole—CYP4A11—Dexamethasone—systemic lupus erythematosus	0.0777	0.112	CbGbCtD
Lansoprazole—ABCG2—Leflunomide—systemic lupus erythematosus	0.0498	0.0718	CbGbCtD
Lansoprazole—CYP1B1—Dexamethasone—systemic lupus erythematosus	0.0323	0.0466	CbGbCtD
Lansoprazole—ABCG2—Mycophenolate mofetil—systemic lupus erythematosus	0.0307	0.0444	CbGbCtD
Lansoprazole—ABCG2—Hydrocortisone—systemic lupus erythematosus	0.0247	0.0356	CbGbCtD
Lansoprazole—ABCG2—Cyclosporine—systemic lupus erythematosus	0.0233	0.0336	CbGbCtD
Lansoprazole—CYP1A2—Leflunomide—systemic lupus erythematosus	0.0205	0.0296	CbGbCtD
Lansoprazole—CYP2C8—Dapsone—systemic lupus erythematosus	0.0189	0.0273	CbGbCtD
Lansoprazole—CYP2C9—Leflunomide—systemic lupus erythematosus	0.0185	0.0267	CbGbCtD
Lansoprazole—CYP2C8—Mycophenolate mofetil—systemic lupus erythematosus	0.0164	0.0236	CbGbCtD
Lansoprazole—CYP2C19—Dapsone—systemic lupus erythematosus	0.0158	0.0229	CbGbCtD
Lansoprazole—ABCG2—Dexamethasone—systemic lupus erythematosus	0.0153	0.0221	CbGbCtD
Lansoprazole—ABCB1—Methylprednisolone—systemic lupus erythematosus	0.0146	0.0211	CbGbCtD
Lansoprazole—CYP1A1—Dexamethasone—systemic lupus erythematosus	0.0142	0.0204	CbGbCtD
Lansoprazole—CYP2C9—Dapsone—systemic lupus erythematosus	0.0132	0.019	CbGbCtD
Lansoprazole—CYP2C8—Hydrocortisone—systemic lupus erythematosus	0.0131	0.019	CbGbCtD
Lansoprazole—CYP2C8—Cyclosporine—systemic lupus erythematosus	0.0124	0.0179	CbGbCtD
Lansoprazole—ABCG2—Methotrexate—systemic lupus erythematosus	0.0123	0.0178	CbGbCtD
Lansoprazole—ABCB1—Mycophenolate mofetil—systemic lupus erythematosus	0.0111	0.016	CbGbCtD
Lansoprazole—CYP2C19—Prednisone—systemic lupus erythematosus	0.011	0.0159	CbGbCtD
Lansoprazole—CYP2C19—Cyclosporine—systemic lupus erythematosus	0.0104	0.015	CbGbCtD
Lansoprazole—ABCB1—Betamethasone—systemic lupus erythematosus	0.00951	0.0137	CbGbCtD
Lansoprazole—ABCB1—Prednisolone—systemic lupus erythematosus	0.00938	0.0135	CbGbCtD
Lansoprazole—CYP2C9—cardial valve—systemic lupus erythematosus	0.00901	0.153	CbGeAlD
Lansoprazole—ABCB1—Hydrocortisone—systemic lupus erythematosus	0.00889	0.0128	CbGbCtD
Lansoprazole—ABCB1—Prednisone—systemic lupus erythematosus	0.00886	0.0128	CbGbCtD
Lansoprazole—CYP3A4—Methylprednisolone—systemic lupus erythematosus	0.00876	0.0127	CbGbCtD
Lansoprazole—CYP2C9—Cyclosporine—systemic lupus erythematosus	0.00866	0.0125	CbGbCtD
Lansoprazole—ABCB1—Cyclosporine—systemic lupus erythematosus	0.0084	0.0121	CbGbCtD
Lansoprazole—CYP2C8—Dexamethasone—systemic lupus erythematosus	0.00817	0.0118	CbGbCtD
Lansoprazole—CYP2D6—Cyclosporine—systemic lupus erythematosus	0.00791	0.0114	CbGbCtD
Lansoprazole—CYP3A4—Dapsone—systemic lupus erythematosus	0.00766	0.0111	CbGbCtD
Lansoprazole—CYP2C19—Dexamethasone—systemic lupus erythematosus	0.00686	0.0099	CbGbCtD
Lansoprazole—CYP3A4—Mycophenolate mofetil—systemic lupus erythematosus	0.00664	0.00959	CbGbCtD
Lansoprazole—CYP3A4—Triamcinolone—systemic lupus erythematosus	0.00664	0.00959	CbGbCtD
Lansoprazole—CYP2C9—Dexamethasone—systemic lupus erythematosus	0.0057	0.00823	CbGbCtD
Lansoprazole—CYP3A4—Betamethasone—systemic lupus erythematosus	0.0057	0.00823	CbGbCtD
Lansoprazole—CYP3A4—Prednisolone—systemic lupus erythematosus	0.00562	0.00812	CbGbCtD
Lansoprazole—ABCB1—Dexamethasone—systemic lupus erythematosus	0.00553	0.00799	CbGbCtD
Lansoprazole—CYP3A4—Hydrocortisone—systemic lupus erythematosus	0.00533	0.00769	CbGbCtD
Lansoprazole—CYP3A4—Prednisone—systemic lupus erythematosus	0.00531	0.00766	CbGbCtD
Lansoprazole—CYP2D6—Dexamethasone—systemic lupus erythematosus	0.00521	0.00752	CbGbCtD
Lansoprazole—CYP3A4—Cyclosporine—systemic lupus erythematosus	0.00503	0.00727	CbGbCtD
Lansoprazole—ABCB1—Methotrexate—systemic lupus erythematosus	0.00445	0.00642	CbGbCtD
Lansoprazole—ATP4A—blood plasma—systemic lupus erythematosus	0.00374	0.0635	CbGeAlD
Lansoprazole—CYP3A4—Dexamethasone—systemic lupus erythematosus	0.00331	0.00478	CbGbCtD
Lansoprazole—MAPT—nephron tubule—systemic lupus erythematosus	0.0026	0.0441	CbGeAlD
Lansoprazole—CYP2C19—urine—systemic lupus erythematosus	0.00251	0.0425	CbGeAlD
Lansoprazole—MAPT—cortex of kidney—systemic lupus erythematosus	0.00223	0.0377	CbGeAlD
Lansoprazole—CYP4A11—kidney—systemic lupus erythematosus	0.00211	0.0357	CbGeAlD
Lansoprazole—CYP4A11—cortex of kidney—systemic lupus erythematosus	0.00205	0.0348	CbGeAlD
Lansoprazole—CYP1A2—urine—systemic lupus erythematosus	0.00205	0.0347	CbGeAlD
Lansoprazole—ATP4A—connective tissue—systemic lupus erythematosus	0.00199	0.0338	CbGeAlD
Lansoprazole—CYP2C9—urine—systemic lupus erythematosus	0.00194	0.0329	CbGeAlD
Lansoprazole—MAPT—tendon—systemic lupus erythematosus	0.00185	0.0313	CbGeAlD
Lansoprazole—ATP4A—kidney—systemic lupus erythematosus	0.0017	0.0288	CbGeAlD
Lansoprazole—CYP3A4—urine—systemic lupus erythematosus	0.00148	0.0251	CbGeAlD
Lansoprazole—CYP2D6—urine—systemic lupus erythematosus	0.00146	0.0247	CbGeAlD
Lansoprazole—CYP2C19—blood plasma—systemic lupus erythematosus	0.00131	0.0222	CbGeAlD
Lansoprazole—CYP2C8—blood plasma—systemic lupus erythematosus	0.00114	0.0194	CbGeAlD
Lansoprazole—ATP4A—nervous system—systemic lupus erythematosus	0.00111	0.0189	CbGeAlD
Lansoprazole—ATP4A—central nervous system—systemic lupus erythematosus	0.00107	0.0182	CbGeAlD
Lansoprazole—CYP1A2—blood plasma—systemic lupus erythematosus	0.00107	0.0181	CbGeAlD
Lansoprazole—CYP2C9—blood plasma—systemic lupus erythematosus	0.00101	0.0172	CbGeAlD
Lansoprazole—CYP1B1—connective tissue—systemic lupus erythematosus	0.000794	0.0135	CbGeAlD
Lansoprazole—CYP3A4—blood plasma—systemic lupus erythematosus	0.000773	0.0131	CbGeAlD
Lansoprazole—CYP1B1—nephron tubule—systemic lupus erythematosus	0.000769	0.013	CbGeAlD
Lansoprazole—CYP2D6—blood plasma—systemic lupus erythematosus	0.000761	0.0129	CbGeAlD
Lansoprazole—CYP1B1—skin of body—systemic lupus erythematosus	0.000717	0.0122	CbGeAlD
Lansoprazole—CYP1B1—kidney—systemic lupus erythematosus	0.000676	0.0115	CbGeAlD
Lansoprazole—CYP1B1—cortex of kidney—systemic lupus erythematosus	0.000658	0.0112	CbGeAlD
Lansoprazole—CYP1B1—lymphoid tissue—systemic lupus erythematosus	0.00058	0.00984	CbGeAlD
Lansoprazole—ABCG2—nephron tubule—systemic lupus erythematosus	0.000572	0.00971	CbGeAlD
Lansoprazole—ABCB1—blood plasma—systemic lupus erythematosus	0.000547	0.00928	CbGeAlD
Lansoprazole—CYP1B1—tendon—systemic lupus erythematosus	0.000546	0.00925	CbGeAlD
Lansoprazole—CYP2C8—kidney—systemic lupus erythematosus	0.000517	0.00877	CbGeAlD
Lansoprazole—CYP1A1—skin of body—systemic lupus erythematosus	0.000507	0.00859	CbGeAlD
Lansoprazole—CYP1B1—lung—systemic lupus erythematosus	0.000479	0.00812	CbGeAlD
Lansoprazole—CYP1A1—kidney—systemic lupus erythematosus	0.000478	0.0081	CbGeAlD
Lansoprazole—CYP1B1—nervous system—systemic lupus erythematosus	0.000443	0.00752	CbGeAlD
Lansoprazole—CYP1B1—central nervous system—systemic lupus erythematosus	0.000427	0.00724	CbGeAlD
Lansoprazole—ABCG2—bone marrow—systemic lupus erythematosus	0.000393	0.00667	CbGeAlD
Lansoprazole—ABCG2—lung—systemic lupus erythematosus	0.000356	0.00604	CbGeAlD
Lansoprazole—CYP3A4—kidney—systemic lupus erythematosus	0.00035	0.00594	CbGeAlD
Lansoprazole—CYP2D6—kidney—systemic lupus erythematosus	0.000345	0.00585	CbGeAlD
Lansoprazole—CYP1A2—lung—systemic lupus erythematosus	0.000343	0.00582	CbGeAlD
Lansoprazole—CYP1A1—lung—systemic lupus erythematosus	0.000338	0.00574	CbGeAlD
Lansoprazole—CYP1A1—nervous system—systemic lupus erythematosus	0.000313	0.00531	CbGeAlD
Lansoprazole—CYP1A1—central nervous system—systemic lupus erythematosus	0.000302	0.00512	CbGeAlD
Lansoprazole—ABCB1—nephron tubule—systemic lupus erythematosus	0.000282	0.00479	CbGeAlD
Lansoprazole—ABCB1—kidney—systemic lupus erythematosus	0.000248	0.00421	CbGeAlD
Lansoprazole—ABCB1—cortex of kidney—systemic lupus erythematosus	0.000242	0.0041	CbGeAlD
Lansoprazole—CYP3A4—nervous system—systemic lupus erythematosus	0.00023	0.0039	CbGeAlD
Lansoprazole—CYP2D6—nervous system—systemic lupus erythematosus	0.000226	0.00384	CbGeAlD
Lansoprazole—CYP3A4—central nervous system—systemic lupus erythematosus	0.000221	0.00375	CbGeAlD
Lansoprazole—CYP2D6—central nervous system—systemic lupus erythematosus	0.000218	0.00369	CbGeAlD
Lansoprazole—ABCB1—lymphoid tissue—systemic lupus erythematosus	0.000213	0.00361	CbGeAlD
Lansoprazole—ABCB1—bone marrow—systemic lupus erythematosus	0.000194	0.00329	CbGeAlD
Lansoprazole—ABCB1—lung—systemic lupus erythematosus	0.000176	0.00298	CbGeAlD
Lansoprazole—ABCB1—nervous system—systemic lupus erythematosus	0.000163	0.00276	CbGeAlD
Lansoprazole—ABCB1—central nervous system—systemic lupus erythematosus	0.000157	0.00266	CbGeAlD
Lansoprazole—Oedema—Betamethasone—systemic lupus erythematosus	6.14e-05	0.000268	CcSEcCtD
Lansoprazole—Anaphylactic shock—Betamethasone—systemic lupus erythematosus	6.14e-05	0.000268	CcSEcCtD
Lansoprazole—Oedema—Dexamethasone—systemic lupus erythematosus	6.14e-05	0.000268	CcSEcCtD
Lansoprazole—Insomnia—Triamcinolone—systemic lupus erythematosus	6.12e-05	0.000268	CcSEcCtD
Lansoprazole—Insomnia—Methylprednisolone—systemic lupus erythematosus	6.1e-05	0.000267	CcSEcCtD
Lansoprazole—Infection—Dexamethasone—systemic lupus erythematosus	6.1e-05	0.000267	CcSEcCtD
Lansoprazole—Infection—Betamethasone—systemic lupus erythematosus	6.1e-05	0.000267	CcSEcCtD
Lansoprazole—Ill-defined disorder—Prednisone—systemic lupus erythematosus	6.08e-05	0.000266	CcSEcCtD
Lansoprazole—Paraesthesia—Triamcinolone—systemic lupus erythematosus	6.07e-05	0.000266	CcSEcCtD
Lansoprazole—Feeling abnormal—Prednisolone—systemic lupus erythematosus	6.06e-05	0.000265	CcSEcCtD
Lansoprazole—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	6.06e-05	0.000265	CcSEcCtD
Lansoprazole—Visual impairment—Methotrexate—systemic lupus erythematosus	6.06e-05	0.000265	CcSEcCtD
Lansoprazole—Anaemia—Prednisone—systemic lupus erythematosus	6.05e-05	0.000265	CcSEcCtD
Lansoprazole—Shock—Betamethasone—systemic lupus erythematosus	6.04e-05	0.000264	CcSEcCtD
Lansoprazole—Shock—Dexamethasone—systemic lupus erythematosus	6.04e-05	0.000264	CcSEcCtD
Lansoprazole—Dyspnoea—Triamcinolone—systemic lupus erythematosus	6.03e-05	0.000264	CcSEcCtD
Lansoprazole—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	6.02e-05	0.000263	CcSEcCtD
Lansoprazole—Nervous system disorder—Betamethasone—systemic lupus erythematosus	6.02e-05	0.000263	CcSEcCtD
Lansoprazole—Agitation—Prednisone—systemic lupus erythematosus	6.02e-05	0.000263	CcSEcCtD
Lansoprazole—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	6.01e-05	0.000263	CcSEcCtD
Lansoprazole—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	6.01e-05	0.000263	CcSEcCtD
Lansoprazole—Tachycardia—Betamethasone—systemic lupus erythematosus	5.99e-05	0.000262	CcSEcCtD
Lansoprazole—Tachycardia—Dexamethasone—systemic lupus erythematosus	5.99e-05	0.000262	CcSEcCtD
Lansoprazole—Angioedema—Prednisone—systemic lupus erythematosus	5.98e-05	0.000262	CcSEcCtD
Lansoprazole—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	5.96e-05	0.000261	CcSEcCtD
Lansoprazole—Dyspepsia—Triamcinolone—systemic lupus erythematosus	5.95e-05	0.00026	CcSEcCtD
Lansoprazole—Erythema multiforme—Methotrexate—systemic lupus erythematosus	5.94e-05	0.00026	CcSEcCtD
Lansoprazole—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	5.94e-05	0.00026	CcSEcCtD
Lansoprazole—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	5.93e-05	0.00026	CcSEcCtD
Lansoprazole—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	5.93e-05	0.00026	CcSEcCtD
Lansoprazole—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	5.92e-05	0.000259	CcSEcCtD
Lansoprazole—Malaise—Prednisone—systemic lupus erythematosus	5.91e-05	0.000258	CcSEcCtD
Lansoprazole—Vertigo—Prednisone—systemic lupus erythematosus	5.88e-05	0.000257	CcSEcCtD
Lansoprazole—Eye disorder—Methotrexate—systemic lupus erythematosus	5.88e-05	0.000257	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	5.87e-05	0.000257	CcSEcCtD
Lansoprazole—Syncope—Prednisone—systemic lupus erythematosus	5.87e-05	0.000257	CcSEcCtD
Lansoprazole—Tinnitus—Methotrexate—systemic lupus erythematosus	5.86e-05	0.000256	CcSEcCtD
Lansoprazole—Anorexia—Dexamethasone—systemic lupus erythematosus	5.85e-05	0.000256	CcSEcCtD
Lansoprazole—Anorexia—Betamethasone—systemic lupus erythematosus	5.85e-05	0.000256	CcSEcCtD
Lansoprazole—Urticaria—Prednisolone—systemic lupus erythematosus	5.84e-05	0.000256	CcSEcCtD
Lansoprazole—Cardiac disorder—Methotrexate—systemic lupus erythematosus	5.84e-05	0.000255	CcSEcCtD
Lansoprazole—Fatigue—Triamcinolone—systemic lupus erythematosus	5.83e-05	0.000255	CcSEcCtD
Lansoprazole—Fatigue—Methylprednisolone—systemic lupus erythematosus	5.82e-05	0.000255	CcSEcCtD
Lansoprazole—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	5.81e-05	0.000254	CcSEcCtD
Lansoprazole—Asthenia—Cyclosporine—systemic lupus erythematosus	5.8e-05	0.000254	CcSEcCtD
Lansoprazole—Pain—Triamcinolone—systemic lupus erythematosus	5.78e-05	0.000253	CcSEcCtD
Lansoprazole—Loss of consciousness—Prednisone—systemic lupus erythematosus	5.76e-05	0.000252	CcSEcCtD
Lansoprazole—Hypotension—Dexamethasone—systemic lupus erythematosus	5.74e-05	0.000251	CcSEcCtD
Lansoprazole—Hypotension—Betamethasone—systemic lupus erythematosus	5.74e-05	0.000251	CcSEcCtD
Lansoprazole—Pruritus—Cyclosporine—systemic lupus erythematosus	5.72e-05	0.00025	CcSEcCtD
Lansoprazole—Urticaria—Hydrocortisone—systemic lupus erythematosus	5.71e-05	0.00025	CcSEcCtD
Lansoprazole—Angiopathy—Methotrexate—systemic lupus erythematosus	5.7e-05	0.00025	CcSEcCtD
Lansoprazole—Immune system disorder—Methotrexate—systemic lupus erythematosus	5.68e-05	0.000248	CcSEcCtD
Lansoprazole—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	5.68e-05	0.000248	CcSEcCtD
Lansoprazole—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	5.68e-05	0.000248	CcSEcCtD
Lansoprazole—Convulsion—Prednisone—systemic lupus erythematosus	5.67e-05	0.000248	CcSEcCtD
Lansoprazole—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	5.67e-05	0.000248	CcSEcCtD
Lansoprazole—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	5.66e-05	0.000247	CcSEcCtD
Lansoprazole—Hypertension—Prednisone—systemic lupus erythematosus	5.65e-05	0.000247	CcSEcCtD
Lansoprazole—Chills—Methotrexate—systemic lupus erythematosus	5.64e-05	0.000247	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	5.59e-05	0.000245	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	5.59e-05	0.000245	CcSEcCtD
Lansoprazole—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	5.58e-05	0.000244	CcSEcCtD
Lansoprazole—Arthralgia—Prednisone—systemic lupus erythematosus	5.58e-05	0.000244	CcSEcCtD
Lansoprazole—Myalgia—Prednisone—systemic lupus erythematosus	5.58e-05	0.000244	CcSEcCtD
Lansoprazole—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	5.57e-05	0.000244	CcSEcCtD
Lansoprazole—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	5.56e-05	0.000243	CcSEcCtD
Lansoprazole—Anxiety—Prednisone—systemic lupus erythematosus	5.56e-05	0.000243	CcSEcCtD
Lansoprazole—Alopecia—Methotrexate—systemic lupus erythematosus	5.56e-05	0.000243	CcSEcCtD
Lansoprazole—Insomnia—Dexamethasone—systemic lupus erythematosus	5.55e-05	0.000243	CcSEcCtD
Lansoprazole—Insomnia—Betamethasone—systemic lupus erythematosus	5.55e-05	0.000243	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	5.54e-05	0.000242	CcSEcCtD
Lansoprazole—Diarrhoea—Cyclosporine—systemic lupus erythematosus	5.53e-05	0.000242	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	5.52e-05	0.000241	CcSEcCtD
Lansoprazole—Paraesthesia—Dexamethasone—systemic lupus erythematosus	5.51e-05	0.000241	CcSEcCtD
Lansoprazole—Paraesthesia—Betamethasone—systemic lupus erythematosus	5.51e-05	0.000241	CcSEcCtD
Lansoprazole—Discomfort—Prednisone—systemic lupus erythematosus	5.51e-05	0.000241	CcSEcCtD
Lansoprazole—Mental disorder—Methotrexate—systemic lupus erythematosus	5.51e-05	0.000241	CcSEcCtD
Lansoprazole—Erythema—Methotrexate—systemic lupus erythematosus	5.47e-05	0.000239	CcSEcCtD
Lansoprazole—Malnutrition—Methotrexate—systemic lupus erythematosus	5.47e-05	0.000239	CcSEcCtD
Lansoprazole—Hypersensitivity—Prednisolone—systemic lupus erythematosus	5.42e-05	0.000237	CcSEcCtD
Lansoprazole—Dyspepsia—Betamethasone—systemic lupus erythematosus	5.4e-05	0.000236	CcSEcCtD
Lansoprazole—Dyspepsia—Dexamethasone—systemic lupus erythematosus	5.4e-05	0.000236	CcSEcCtD
Lansoprazole—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	5.4e-05	0.000236	CcSEcCtD
Lansoprazole—Urticaria—Triamcinolone—systemic lupus erythematosus	5.37e-05	0.000235	CcSEcCtD
Lansoprazole—Urticaria—Methylprednisolone—systemic lupus erythematosus	5.36e-05	0.000235	CcSEcCtD
Lansoprazole—Dysgeusia—Methotrexate—systemic lupus erythematosus	5.36e-05	0.000234	CcSEcCtD
Lansoprazole—Body temperature increased—Triamcinolone—systemic lupus erythematosus	5.35e-05	0.000234	CcSEcCtD
Lansoprazole—Dizziness—Cyclosporine—systemic lupus erythematosus	5.35e-05	0.000234	CcSEcCtD
Lansoprazole—Oedema—Prednisone—systemic lupus erythematosus	5.35e-05	0.000234	CcSEcCtD
Lansoprazole—Anaphylactic shock—Prednisone—systemic lupus erythematosus	5.35e-05	0.000234	CcSEcCtD
Lansoprazole—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	5.34e-05	0.000233	CcSEcCtD
Lansoprazole—Decreased appetite—Dexamethasone—systemic lupus erythematosus	5.34e-05	0.000233	CcSEcCtD
Lansoprazole—Decreased appetite—Betamethasone—systemic lupus erythematosus	5.34e-05	0.000233	CcSEcCtD
Lansoprazole—Infection—Prednisone—systemic lupus erythematosus	5.31e-05	0.000232	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	5.3e-05	0.000232	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	5.3e-05	0.000232	CcSEcCtD
Lansoprazole—Back pain—Methotrexate—systemic lupus erythematosus	5.29e-05	0.000232	CcSEcCtD
Lansoprazole—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	5.29e-05	0.000232	CcSEcCtD
Lansoprazole—Fatigue—Betamethasone—systemic lupus erythematosus	5.29e-05	0.000231	CcSEcCtD
Lansoprazole—Fatigue—Dexamethasone—systemic lupus erythematosus	5.29e-05	0.000231	CcSEcCtD
Lansoprazole—Shock—Prednisone—systemic lupus erythematosus	5.26e-05	0.00023	CcSEcCtD
Lansoprazole—Pain—Betamethasone—systemic lupus erythematosus	5.25e-05	0.00023	CcSEcCtD
Lansoprazole—Pain—Dexamethasone—systemic lupus erythematosus	5.25e-05	0.00023	CcSEcCtD
Lansoprazole—Nervous system disorder—Prednisone—systemic lupus erythematosus	5.24e-05	0.000229	CcSEcCtD
Lansoprazole—Tachycardia—Prednisone—systemic lupus erythematosus	5.22e-05	0.000228	CcSEcCtD
Lansoprazole—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	5.21e-05	0.000228	CcSEcCtD
Lansoprazole—Skin disorder—Prednisone—systemic lupus erythematosus	5.19e-05	0.000227	CcSEcCtD
Lansoprazole—Hyperhidrosis—Prednisone—systemic lupus erythematosus	5.17e-05	0.000226	CcSEcCtD
Lansoprazole—Vision blurred—Methotrexate—systemic lupus erythematosus	5.16e-05	0.000226	CcSEcCtD
Lansoprazole—Asthenia—Hydrocortisone—systemic lupus erythematosus	5.15e-05	0.000225	CcSEcCtD
Lansoprazole—Vomiting—Cyclosporine—systemic lupus erythematosus	5.14e-05	0.000225	CcSEcCtD
Lansoprazole—Rash—Cyclosporine—systemic lupus erythematosus	5.1e-05	0.000223	CcSEcCtD
Lansoprazole—Anorexia—Prednisone—systemic lupus erythematosus	5.09e-05	0.000223	CcSEcCtD
Lansoprazole—Dermatitis—Cyclosporine—systemic lupus erythematosus	5.09e-05	0.000223	CcSEcCtD
Lansoprazole—Pruritus—Hydrocortisone—systemic lupus erythematosus	5.08e-05	0.000222	CcSEcCtD
Lansoprazole—Ill-defined disorder—Methotrexate—systemic lupus erythematosus	5.08e-05	0.000222	CcSEcCtD
Lansoprazole—Headache—Cyclosporine—systemic lupus erythematosus	5.06e-05	0.000222	CcSEcCtD
Lansoprazole—Anaemia—Methotrexate—systemic lupus erythematosus	5.06e-05	0.000221	CcSEcCtD
Lansoprazole—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	5.06e-05	0.000221	CcSEcCtD
Lansoprazole—Feeling abnormal—Betamethasone—systemic lupus erythematosus	5.06e-05	0.000221	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	5.02e-05	0.00022	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	5.02e-05	0.00022	CcSEcCtD
Lansoprazole—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	5.01e-05	0.000219	CcSEcCtD
Lansoprazole—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	4.98e-05	0.000218	CcSEcCtD
Lansoprazole—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	4.97e-05	0.000218	CcSEcCtD
Lansoprazole—Rash—Mycophenolate mofetil—systemic lupus erythematosus	4.97e-05	0.000217	CcSEcCtD
Lansoprazole—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	4.97e-05	0.000217	CcSEcCtD
Lansoprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	4.96e-05	0.0025	CbGpPWpGaD
Lansoprazole—Headache—Mycophenolate mofetil—systemic lupus erythematosus	4.94e-05	0.000216	CcSEcCtD
Lansoprazole—Malaise—Methotrexate—systemic lupus erythematosus	4.94e-05	0.000216	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	4.93e-05	0.00249	CbGpPWpGaD
Lansoprazole—Vertigo—Methotrexate—systemic lupus erythematosus	4.92e-05	0.000215	CcSEcCtD
Lansoprazole—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	4.92e-05	0.000215	CcSEcCtD
Lansoprazole—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	4.91e-05	0.00248	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—CXCL12—systemic lupus erythematosus	4.91e-05	0.00248	CbGpPWpGaD
Lansoprazole—Leukopenia—Methotrexate—systemic lupus erythematosus	4.9e-05	0.000214	CcSEcCtD
Lansoprazole—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	4.89e-05	0.00247	CbGpPWpGaD
Lansoprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	4.89e-05	0.00247	CbGpPWpGaD
Lansoprazole—Urticaria—Dexamethasone—systemic lupus erythematosus	4.88e-05	0.000213	CcSEcCtD
Lansoprazole—Urticaria—Betamethasone—systemic lupus erythematosus	4.88e-05	0.000213	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	4.87e-05	0.000213	CcSEcCtD
Lansoprazole—Dizziness—Prednisolone—systemic lupus erythematosus	4.86e-05	0.000213	CcSEcCtD
Lansoprazole—Asthenia—Triamcinolone—systemic lupus erythematosus	4.85e-05	0.000212	CcSEcCtD
Lansoprazole—Abdominal pain—Dexamethasone—systemic lupus erythematosus	4.85e-05	0.000212	CcSEcCtD
Lansoprazole—Body temperature increased—Betamethasone—systemic lupus erythematosus	4.85e-05	0.000212	CcSEcCtD
Lansoprazole—Abdominal pain—Betamethasone—systemic lupus erythematosus	4.85e-05	0.000212	CcSEcCtD
Lansoprazole—Body temperature increased—Dexamethasone—systemic lupus erythematosus	4.85e-05	0.000212	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—CD40—systemic lupus erythematosus	4.85e-05	0.00245	CbGpPWpGaD
Lansoprazole—Asthenia—Methylprednisolone—systemic lupus erythematosus	4.84e-05	0.000212	CcSEcCtD
Lansoprazole—Insomnia—Prednisone—systemic lupus erythematosus	4.83e-05	0.000211	CcSEcCtD
Lansoprazole—Nausea—Cyclosporine—systemic lupus erythematosus	4.8e-05	0.00021	CcSEcCtD
Lansoprazole—Paraesthesia—Prednisone—systemic lupus erythematosus	4.8e-05	0.00021	CcSEcCtD
Lansoprazole—Pruritus—Triamcinolone—systemic lupus erythematosus	4.79e-05	0.000209	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—CTLA4—systemic lupus erythematosus	4.78e-05	0.00241	CbGpPWpGaD
Lansoprazole—Cough—Methotrexate—systemic lupus erythematosus	4.78e-05	0.000209	CcSEcCtD
Lansoprazole—Pruritus—Methylprednisolone—systemic lupus erythematosus	4.78e-05	0.000209	CcSEcCtD
Lansoprazole—Dizziness—Hydrocortisone—systemic lupus erythematosus	4.75e-05	0.000208	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	4.75e-05	0.0024	CbGpPWpGaD
Lansoprazole—Convulsion—Methotrexate—systemic lupus erythematosus	4.74e-05	0.000207	CcSEcCtD
Lansoprazole—Dyspepsia—Prednisone—systemic lupus erythematosus	4.7e-05	0.000206	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	4.69e-05	0.00237	CbGpPWpGaD
Lansoprazole—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	4.68e-05	0.000205	CcSEcCtD
Lansoprazole—Chest pain—Methotrexate—systemic lupus erythematosus	4.66e-05	0.000204	CcSEcCtD
Lansoprazole—Arthralgia—Methotrexate—systemic lupus erythematosus	4.66e-05	0.000204	CcSEcCtD
Lansoprazole—Myalgia—Methotrexate—systemic lupus erythematosus	4.66e-05	0.000204	CcSEcCtD
Lansoprazole—Decreased appetite—Prednisone—systemic lupus erythematosus	4.65e-05	0.000203	CcSEcCtD
Lansoprazole—Rash—Prednisolone—systemic lupus erythematosus	4.64e-05	0.000203	CcSEcCtD
Lansoprazole—CYP2C8—Biological oxidations—NAT2—systemic lupus erythematosus	4.64e-05	0.00234	CbGpPWpGaD
Lansoprazole—Dermatitis—Prednisolone—systemic lupus erythematosus	4.63e-05	0.000203	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	4.63e-05	0.000202	CcSEcCtD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	4.62e-05	0.00233	CbGpPWpGaD
Lansoprazole—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	4.62e-05	0.000202	CcSEcCtD
Lansoprazole—Fatigue—Prednisone—systemic lupus erythematosus	4.61e-05	0.000202	CcSEcCtD
Lansoprazole—Headache—Prednisolone—systemic lupus erythematosus	4.61e-05	0.000202	CcSEcCtD
Lansoprazole—Discomfort—Methotrexate—systemic lupus erythematosus	4.6e-05	0.000201	CcSEcCtD
Lansoprazole—CYP1B1—Biological oxidations—RXRA—systemic lupus erythematosus	4.6e-05	0.00233	CbGpPWpGaD
Lansoprazole—CYP2C8—Metapathway biotransformation—NAT2—systemic lupus erythematosus	4.57e-05	0.00231	CbGpPWpGaD
Lansoprazole—Constipation—Prednisone—systemic lupus erythematosus	4.57e-05	0.0002	CcSEcCtD
Lansoprazole—Vomiting—Hydrocortisone—systemic lupus erythematosus	4.57e-05	0.0002	CcSEcCtD
Lansoprazole—Rash—Hydrocortisone—systemic lupus erythematosus	4.53e-05	0.000198	CcSEcCtD
Lansoprazole—Dermatitis—Hydrocortisone—systemic lupus erythematosus	4.53e-05	0.000198	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—TGFB1—systemic lupus erythematosus	4.52e-05	0.00228	CbGpPWpGaD
Lansoprazole—Confusional state—Methotrexate—systemic lupus erythematosus	4.5e-05	0.000197	CcSEcCtD
Lansoprazole—Headache—Hydrocortisone—systemic lupus erythematosus	4.5e-05	0.000197	CcSEcCtD
Lansoprazole—MAPT—Apoptosis—TNF—systemic lupus erythematosus	4.5e-05	0.00227	CbGpPWpGaD
Lansoprazole—Dizziness—Triamcinolone—systemic lupus erythematosus	4.47e-05	0.000196	CcSEcCtD
Lansoprazole—Anaphylactic shock—Methotrexate—systemic lupus erythematosus	4.47e-05	0.000195	CcSEcCtD
Lansoprazole—Dizziness—Methylprednisolone—systemic lupus erythematosus	4.46e-05	0.000195	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	4.44e-05	0.00224	CbGpPWpGaD
Lansoprazole—Infection—Methotrexate—systemic lupus erythematosus	4.44e-05	0.000194	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	4.43e-05	0.00224	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—TNF—systemic lupus erythematosus	4.43e-05	0.00224	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Prednisone—systemic lupus erythematosus	4.4e-05	0.000193	CcSEcCtD
Lansoprazole—Asthenia—Betamethasone—systemic lupus erythematosus	4.4e-05	0.000193	CcSEcCtD
Lansoprazole—Asthenia—Dexamethasone—systemic lupus erythematosus	4.4e-05	0.000193	CcSEcCtD
Lansoprazole—Nervous system disorder—Methotrexate—systemic lupus erythematosus	4.38e-05	0.000192	CcSEcCtD
Lansoprazole—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	4.37e-05	0.000191	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	4.37e-05	0.000191	CcSEcCtD
Lansoprazole—Nausea—Prednisolone—systemic lupus erythematosus	4.37e-05	0.000191	CcSEcCtD
Lansoprazole—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	4.37e-05	0.00221	CbGpPWpGaD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—systemic lupus erythematosus	4.35e-05	0.0022	CbGpPWpGaD
Lansoprazole—Pruritus—Betamethasone—systemic lupus erythematosus	4.34e-05	0.00019	CcSEcCtD
Lansoprazole—Pruritus—Dexamethasone—systemic lupus erythematosus	4.34e-05	0.00019	CcSEcCtD
Lansoprazole—Skin disorder—Methotrexate—systemic lupus erythematosus	4.34e-05	0.00019	CcSEcCtD
Lansoprazole—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	4.32e-05	0.000189	CcSEcCtD
Lansoprazole—Vomiting—Triamcinolone—systemic lupus erythematosus	4.3e-05	0.000188	CcSEcCtD
Lansoprazole—Vomiting—Methylprednisolone—systemic lupus erythematosus	4.29e-05	0.000188	CcSEcCtD
Lansoprazole—Nausea—Hydrocortisone—systemic lupus erythematosus	4.27e-05	0.000187	CcSEcCtD
Lansoprazole—Rash—Triamcinolone—systemic lupus erythematosus	4.26e-05	0.000187	CcSEcCtD
Lansoprazole—Dermatitis—Triamcinolone—systemic lupus erythematosus	4.26e-05	0.000186	CcSEcCtD
Lansoprazole—Anorexia—Methotrexate—systemic lupus erythematosus	4.26e-05	0.000186	CcSEcCtD
Lansoprazole—Rash—Methylprednisolone—systemic lupus erythematosus	4.26e-05	0.000186	CcSEcCtD
Lansoprazole—Dermatitis—Methylprednisolone—systemic lupus erythematosus	4.25e-05	0.000186	CcSEcCtD
Lansoprazole—Urticaria—Prednisone—systemic lupus erythematosus	4.25e-05	0.000186	CcSEcCtD
Lansoprazole—Headache—Triamcinolone—systemic lupus erythematosus	4.24e-05	0.000185	CcSEcCtD
Lansoprazole—Headache—Methylprednisolone—systemic lupus erythematosus	4.23e-05	0.000185	CcSEcCtD
Lansoprazole—Abdominal pain—Prednisone—systemic lupus erythematosus	4.23e-05	0.000185	CcSEcCtD
Lansoprazole—Body temperature increased—Prednisone—systemic lupus erythematosus	4.23e-05	0.000185	CcSEcCtD
Lansoprazole—CYP4A11—PPARA activates gene expression—EP300—systemic lupus erythematosus	4.22e-05	0.00213	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	4.22e-05	0.00213	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TNF—systemic lupus erythematosus	4.22e-05	0.00213	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—HLA-DQA1—systemic lupus erythematosus	4.21e-05	0.00213	CbGpPWpGaD
Lansoprazole—Diarrhoea—Betamethasone—systemic lupus erythematosus	4.2e-05	0.000184	CcSEcCtD
Lansoprazole—Diarrhoea—Dexamethasone—systemic lupus erythematosus	4.2e-05	0.000184	CcSEcCtD
Lansoprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	4.2e-05	0.00212	CbGpPWpGaD
Lansoprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	4.17e-05	0.00211	CbGpPWpGaD
Lansoprazole—Hypotension—Methotrexate—systemic lupus erythematosus	4.17e-05	0.000183	CcSEcCtD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	4.17e-05	0.00211	CbGpPWpGaD
Lansoprazole—CYP2C19—Biological oxidations—NAT2—systemic lupus erythematosus	4.14e-05	0.00209	CbGpPWpGaD
Lansoprazole—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—systemic lupus erythematosus	4.13e-05	0.00209	CbGpPWpGaD
Lansoprazole—CYP2C19—Metapathway biotransformation—NAT2—systemic lupus erythematosus	4.08e-05	0.00206	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	4.07e-05	0.00206	CbGpPWpGaD
Lansoprazole—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	4.07e-05	0.000178	CcSEcCtD
Lansoprazole—Dizziness—Betamethasone—systemic lupus erythematosus	4.06e-05	0.000178	CcSEcCtD
Lansoprazole—Dizziness—Dexamethasone—systemic lupus erythematosus	4.06e-05	0.000178	CcSEcCtD
Lansoprazole—CYP1A1—PPARA activates gene expression—RXRA—systemic lupus erythematosus	4.05e-05	0.00205	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—systemic lupus erythematosus	4.04e-05	0.00204	CbGpPWpGaD
Lansoprazole—Insomnia—Methotrexate—systemic lupus erythematosus	4.04e-05	0.000177	CcSEcCtD
Lansoprazole—Nausea—Triamcinolone—systemic lupus erythematosus	4.02e-05	0.000176	CcSEcCtD
Lansoprazole—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	4.02e-05	0.00203	CbGpPWpGaD
Lansoprazole—Paraesthesia—Methotrexate—systemic lupus erythematosus	4.01e-05	0.000175	CcSEcCtD
Lansoprazole—Nausea—Methylprednisolone—systemic lupus erythematosus	4.01e-05	0.000175	CcSEcCtD
Lansoprazole—Dyspnoea—Methotrexate—systemic lupus erythematosus	3.98e-05	0.000174	CcSEcCtD
Lansoprazole—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	3.98e-05	0.00201	CbGpPWpGaD
Lansoprazole—Somnolence—Methotrexate—systemic lupus erythematosus	3.97e-05	0.000174	CcSEcCtD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—systemic lupus erythematosus	3.97e-05	0.002	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Prednisone—systemic lupus erythematosus	3.94e-05	0.000172	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—HLA-DQB1—systemic lupus erythematosus	3.94e-05	0.00199	CbGpPWpGaD
Lansoprazole—Dyspepsia—Methotrexate—systemic lupus erythematosus	3.93e-05	0.000172	CcSEcCtD
Lansoprazole—Vomiting—Betamethasone—systemic lupus erythematosus	3.9e-05	0.000171	CcSEcCtD
Lansoprazole—Vomiting—Dexamethasone—systemic lupus erythematosus	3.9e-05	0.000171	CcSEcCtD
Lansoprazole—Decreased appetite—Methotrexate—systemic lupus erythematosus	3.88e-05	0.00017	CcSEcCtD
Lansoprazole—Rash—Betamethasone—systemic lupus erythematosus	3.87e-05	0.000169	CcSEcCtD
Lansoprazole—Rash—Dexamethasone—systemic lupus erythematosus	3.87e-05	0.000169	CcSEcCtD
Lansoprazole—Dermatitis—Dexamethasone—systemic lupus erythematosus	3.87e-05	0.000169	CcSEcCtD
Lansoprazole—Dermatitis—Betamethasone—systemic lupus erythematosus	3.87e-05	0.000169	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	3.86e-05	0.000169	CcSEcCtD
Lansoprazole—Fatigue—Methotrexate—systemic lupus erythematosus	3.85e-05	0.000168	CcSEcCtD
Lansoprazole—Headache—Dexamethasone—systemic lupus erythematosus	3.84e-05	0.000168	CcSEcCtD
Lansoprazole—Headache—Betamethasone—systemic lupus erythematosus	3.84e-05	0.000168	CcSEcCtD
Lansoprazole—Asthenia—Prednisone—systemic lupus erythematosus	3.83e-05	0.000168	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	3.83e-05	0.00194	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—systemic lupus erythematosus	3.83e-05	0.00194	CbGpPWpGaD
Lansoprazole—Pain—Methotrexate—systemic lupus erythematosus	3.82e-05	0.000167	CcSEcCtD
Lansoprazole—CYP2D6—Biological oxidations—NAT2—systemic lupus erythematosus	3.81e-05	0.00192	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	3.81e-05	0.00192	CbGpPWpGaD
Lansoprazole—CYP1A1—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	3.78e-05	0.00191	CbGpPWpGaD
Lansoprazole—Pruritus—Prednisone—systemic lupus erythematosus	3.78e-05	0.000165	CcSEcCtD
Lansoprazole—CYP2C9—Biological oxidations—NAT2—systemic lupus erythematosus	3.77e-05	0.00191	CbGpPWpGaD
Lansoprazole—CYP2D6—Metapathway biotransformation—NAT2—systemic lupus erythematosus	3.75e-05	0.0019	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	3.75e-05	0.00189	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—EP300—systemic lupus erythematosus	3.72e-05	0.00188	CbGpPWpGaD
Lansoprazole—CYP2C9—Metapathway biotransformation—NAT2—systemic lupus erythematosus	3.72e-05	0.00188	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	3.72e-05	0.00188	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—CD40LG—systemic lupus erythematosus	3.72e-05	0.00188	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL10—systemic lupus erythematosus	3.72e-05	0.00188	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Methotrexate—systemic lupus erythematosus	3.68e-05	0.000161	CcSEcCtD
Lansoprazole—Diarrhoea—Prednisone—systemic lupus erythematosus	3.66e-05	0.00016	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	3.65e-05	0.00016	CcSEcCtD
Lansoprazole—Nausea—Dexamethasone—systemic lupus erythematosus	3.65e-05	0.000159	CcSEcCtD
Lansoprazole—Nausea—Betamethasone—systemic lupus erythematosus	3.65e-05	0.000159	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—IL4—systemic lupus erythematosus	3.62e-05	0.00183	CbGpPWpGaD
Lansoprazole—Urticaria—Methotrexate—systemic lupus erythematosus	3.55e-05	0.000155	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—systemic lupus erythematosus	3.54e-05	0.00179	CbGpPWpGaD
Lansoprazole—Dizziness—Prednisone—systemic lupus erythematosus	3.53e-05	0.000155	CcSEcCtD
Lansoprazole—Body temperature increased—Methotrexate—systemic lupus erythematosus	3.53e-05	0.000154	CcSEcCtD
Lansoprazole—Abdominal pain—Methotrexate—systemic lupus erythematosus	3.53e-05	0.000154	CcSEcCtD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—systemic lupus erythematosus	3.53e-05	0.00178	CbGpPWpGaD
Lansoprazole—CYP2C8—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	3.47e-05	0.00175	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—FASLG—systemic lupus erythematosus	3.46e-05	0.00175	CbGpPWpGaD
Lansoprazole—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	3.4e-05	0.00172	CbGpPWpGaD
Lansoprazole—Vomiting—Prednisone—systemic lupus erythematosus	3.4e-05	0.000149	CcSEcCtD
Lansoprazole—Rash—Prednisone—systemic lupus erythematosus	3.37e-05	0.000147	CcSEcCtD
Lansoprazole—Dermatitis—Prednisone—systemic lupus erythematosus	3.37e-05	0.000147	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—EP300—systemic lupus erythematosus	3.36e-05	0.0017	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	3.36e-05	0.0017	CbGpPWpGaD
Lansoprazole—Headache—Prednisone—systemic lupus erythematosus	3.35e-05	0.000146	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—FAS—systemic lupus erythematosus	3.33e-05	0.00168	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL2RA—systemic lupus erythematosus	3.31e-05	0.00167	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Methotrexate—systemic lupus erythematosus	3.29e-05	0.000144	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—C3—systemic lupus erythematosus	3.29e-05	0.00166	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	3.25e-05	0.00164	CbGpPWpGaD
Lansoprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—systemic lupus erythematosus	3.24e-05	0.00164	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—NAT2—systemic lupus erythematosus	3.22e-05	0.00163	CbGpPWpGaD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	3.22e-05	0.00163	CbGpPWpGaD
Lansoprazole—Asthenia—Methotrexate—systemic lupus erythematosus	3.2e-05	0.00014	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—systemic lupus erythematosus	3.19e-05	0.00161	CbGpPWpGaD
Lansoprazole—CYP1A2—Metapathway biotransformation—NAT2—systemic lupus erythematosus	3.18e-05	0.00161	CbGpPWpGaD
Lansoprazole—Nausea—Prednisone—systemic lupus erythematosus	3.17e-05	0.000139	CcSEcCtD
Lansoprazole—Pruritus—Methotrexate—systemic lupus erythematosus	3.16e-05	0.000138	CcSEcCtD
Lansoprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	3.1e-05	0.00156	CbGpPWpGaD
Lansoprazole—Diarrhoea—Methotrexate—systemic lupus erythematosus	3.06e-05	0.000134	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—HLA-DRB1—systemic lupus erythematosus	2.99e-05	0.00151	CbGpPWpGaD
Lansoprazole—Dizziness—Methotrexate—systemic lupus erythematosus	2.95e-05	0.000129	CcSEcCtD
Lansoprazole—CYP4A11—NRF2 pathway—TGFB1—systemic lupus erythematosus	2.92e-05	0.00148	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	2.92e-05	0.00148	CbGpPWpGaD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—systemic lupus erythematosus	2.91e-05	0.00147	CbGpPWpGaD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—systemic lupus erythematosus	2.85e-05	0.00144	CbGpPWpGaD
Lansoprazole—Vomiting—Methotrexate—systemic lupus erythematosus	2.84e-05	0.000124	CcSEcCtD
Lansoprazole—CYP1A1—Biological oxidations—RXRA—systemic lupus erythematosus	2.83e-05	0.00143	CbGpPWpGaD
Lansoprazole—CYP2C9—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	2.82e-05	0.00143	CbGpPWpGaD
Lansoprazole—Rash—Methotrexate—systemic lupus erythematosus	2.82e-05	0.000123	CcSEcCtD
Lansoprazole—Dermatitis—Methotrexate—systemic lupus erythematosus	2.81e-05	0.000123	CcSEcCtD
Lansoprazole—Headache—Methotrexate—systemic lupus erythematosus	2.8e-05	0.000122	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—CD80—systemic lupus erythematosus	2.77e-05	0.0014	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	2.74e-05	0.00139	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—systemic lupus erythematosus	2.73e-05	0.00138	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—systemic lupus erythematosus	2.73e-05	0.00138	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	2.73e-05	0.00138	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—systemic lupus erythematosus	2.69e-05	0.00136	CbGpPWpGaD
Lansoprazole—Nausea—Methotrexate—systemic lupus erythematosus	2.65e-05	0.000116	CcSEcCtD
Lansoprazole—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—systemic lupus erythematosus	2.63e-05	0.00133	CbGpPWpGaD
Lansoprazole—CYP2C8—Biological oxidations—RXRA—systemic lupus erythematosus	2.6e-05	0.00131	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—systemic lupus erythematosus	2.58e-05	0.0013	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—PPARG—systemic lupus erythematosus	2.56e-05	0.00129	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—systemic lupus erythematosus	2.52e-05	0.00127	CbGpPWpGaD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—systemic lupus erythematosus	2.5e-05	0.00127	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—NAT2—systemic lupus erythematosus	2.49e-05	0.00126	CbGpPWpGaD
Lansoprazole—CYP3A4—Metapathway biotransformation—NAT2—systemic lupus erythematosus	2.45e-05	0.00124	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—systemic lupus erythematosus	2.44e-05	0.00123	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—systemic lupus erythematosus	2.44e-05	0.00123	CbGpPWpGaD
Lansoprazole—CYP1A2—Arachidonic acid metabolism—PTGS2—systemic lupus erythematosus	2.41e-05	0.00122	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—systemic lupus erythematosus	2.39e-05	0.00121	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—systemic lupus erythematosus	2.38e-05	0.0012	CbGpPWpGaD
Lansoprazole—CYP2C19—Biological oxidations—RXRA—systemic lupus erythematosus	2.32e-05	0.00117	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—systemic lupus erythematosus	2.25e-05	0.00114	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IFNG—systemic lupus erythematosus	2.19e-05	0.0011	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—NAT2—systemic lupus erythematosus	2.18e-05	0.0011	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—systemic lupus erythematosus	2.14e-05	0.00108	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—systemic lupus erythematosus	2.14e-05	0.00108	CbGpPWpGaD
Lansoprazole—CYP2D6—Biological oxidations—RXRA—systemic lupus erythematosus	2.13e-05	0.00108	CbGpPWpGaD
Lansoprazole—CYP2C9—Biological oxidations—RXRA—systemic lupus erythematosus	2.12e-05	0.00107	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—systemic lupus erythematosus	2.08e-05	0.00105	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—systemic lupus erythematosus	2.03e-05	0.00103	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—EP300—systemic lupus erythematosus	2.01e-05	0.00102	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL2—systemic lupus erythematosus	1.94e-05	0.000981	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—systemic lupus erythematosus	1.91e-05	0.000963	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—NAT2—systemic lupus erythematosus	1.9e-05	0.000962	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic lupus erythematosus	1.86e-05	0.000942	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—RXRA—systemic lupus erythematosus	1.81e-05	0.000913	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.77e-05	0.000893	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—systemic lupus erythematosus	1.74e-05	0.000879	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—systemic lupus erythematosus	1.74e-05	0.000879	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.73e-05	0.000875	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—systemic lupus erythematosus	1.73e-05	0.000872	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—systemic lupus erythematosus	1.71e-05	0.000862	CbGpPWpGaD
Lansoprazole—CYP1A1—PPARA activates gene expression—EP300—systemic lupus erythematosus	1.67e-05	0.000846	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—VEGFA—systemic lupus erythematosus	1.65e-05	0.000834	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—systemic lupus erythematosus	1.64e-05	0.000831	CbGpPWpGaD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—systemic lupus erythematosus	1.64e-05	0.000828	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.56e-05	0.000787	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	1.53e-05	0.000773	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—TGFB1—systemic lupus erythematosus	1.52e-05	0.000765	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—TNF—systemic lupus erythematosus	1.41e-05	0.000715	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—NAT2—systemic lupus erythematosus	1.4e-05	0.000709	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—RXRA—systemic lupus erythematosus	1.4e-05	0.000705	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	1.36e-05	0.000688	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—NAT2—systemic lupus erythematosus	1.28e-05	0.000645	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—RXRA—systemic lupus erythematosus	1.22e-05	0.000617	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.13e-05	0.000572	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—systemic lupus erythematosus	1.13e-05	0.00057	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.12e-05	0.000564	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	1.09e-05	0.00055	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—RXRA—systemic lupus erythematosus	1.07e-05	0.000539	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—systemic lupus erythematosus	1.03e-05	0.000522	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1e-05	0.000507	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	9.98e-06	0.000504	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	9.8e-06	0.000495	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	9.04e-06	0.000457	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	8.91e-06	0.00045	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	8.78e-06	0.000444	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	8.68e-06	0.000439	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—NAT2—systemic lupus erythematosus	8.65e-06	0.000437	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	8.6e-06	0.000435	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	8.27e-06	0.000418	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	8.15e-06	0.000412	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	8.12e-06	0.00041	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—NAT2—systemic lupus erythematosus	7.93e-06	0.000401	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—RXRA—systemic lupus erythematosus	7.87e-06	0.000398	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PPARG—systemic lupus erythematosus	7.71e-06	0.00039	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	7.48e-06	0.000378	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	7.3e-06	0.000369	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—RXRA—systemic lupus erythematosus	7.16e-06	0.000362	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NAT2—systemic lupus erythematosus	7.08e-06	0.000358	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	6.98e-06	0.000353	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	6.94e-06	0.000351	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ALB—systemic lupus erythematosus	6.94e-06	0.00035	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NAT2—systemic lupus erythematosus	6.91e-06	0.000349	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	6.87e-06	0.000347	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PPARG—systemic lupus erythematosus	6.74e-06	0.000341	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—NOS3—systemic lupus erythematosus	6.63e-06	0.000335	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NAT2—systemic lupus erythematosus	6.51e-06	0.000329	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NAT2—systemic lupus erythematosus	6.45e-06	0.000326	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	6.3e-06	0.000318	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	6.18e-06	0.000312	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTGS2—systemic lupus erythematosus	6.07e-06	0.000307	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ALB—systemic lupus erythematosus	6.06e-06	0.000306	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—NOS3—systemic lupus erythematosus	5.8e-06	0.000293	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	5.67e-06	0.000286	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	5.62e-06	0.000284	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NAT2—systemic lupus erythematosus	5.51e-06	0.000279	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	5.41e-06	0.000273	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTGS2—systemic lupus erythematosus	5.3e-06	0.000268	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	5.13e-06	0.000259	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	5.06e-06	0.000255	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—EP300—systemic lupus erythematosus	5.05e-06	0.000255	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PPARG—systemic lupus erythematosus	4.97e-06	0.000251	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	4.96e-06	0.00025	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—RXRA—systemic lupus erythematosus	4.85e-06	0.000245	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	4.69e-06	0.000237	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	4.61e-06	0.000233	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PPARG—systemic lupus erythematosus	4.52e-06	0.000228	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	4.5e-06	0.000227	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ALB—systemic lupus erythematosus	4.47e-06	0.000226	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—RXRA—systemic lupus erythematosus	4.44e-06	0.000225	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	4.42e-06	0.000224	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—EP300—systemic lupus erythematosus	4.41e-06	0.000223	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	4.38e-06	0.000221	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—NOS3—systemic lupus erythematosus	4.28e-06	0.000216	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NAT2—systemic lupus erythematosus	4.26e-06	0.000215	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	4.12e-06	0.000208	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ALB—systemic lupus erythematosus	4.07e-06	0.000205	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	4.03e-06	0.000204	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—RXRA—systemic lupus erythematosus	3.97e-06	0.0002	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	3.94e-06	0.000199	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTGS2—systemic lupus erythematosus	3.91e-06	0.000198	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—NOS3—systemic lupus erythematosus	3.89e-06	0.000196	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—RXRA—systemic lupus erythematosus	3.87e-06	0.000196	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	3.68e-06	0.000186	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—RXRA—systemic lupus erythematosus	3.65e-06	0.000184	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—RXRA—systemic lupus erythematosus	3.62e-06	0.000183	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTGS2—systemic lupus erythematosus	3.56e-06	0.00018	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—systemic lupus erythematosus	3.45e-06	0.000174	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	3.36e-06	0.00017	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—EP300—systemic lupus erythematosus	3.25e-06	0.000164	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—RXRA—systemic lupus erythematosus	3.09e-06	0.000156	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PPARG—systemic lupus erythematosus	3.06e-06	0.000155	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—EP300—systemic lupus erythematosus	2.96e-06	0.000149	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	2.87e-06	0.000145	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PPARG—systemic lupus erythematosus	2.81e-06	0.000142	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ALB—systemic lupus erythematosus	2.75e-06	0.000139	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—NOS3—systemic lupus erythematosus	2.63e-06	0.000133	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ALB—systemic lupus erythematosus	2.52e-06	0.000127	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PPARG—systemic lupus erythematosus	2.5e-06	0.000127	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PPARG—systemic lupus erythematosus	2.44e-06	0.000124	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—NOS3—systemic lupus erythematosus	2.41e-06	0.000122	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTGS2—systemic lupus erythematosus	2.41e-06	0.000122	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—RXRA—systemic lupus erythematosus	2.39e-06	0.000121	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PPARG—systemic lupus erythematosus	2.3e-06	0.000116	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PPARG—systemic lupus erythematosus	2.28e-06	0.000115	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ALB—systemic lupus erythematosus	2.25e-06	0.000114	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTGS2—systemic lupus erythematosus	2.21e-06	0.000112	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ALB—systemic lupus erythematosus	2.2e-06	0.000111	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NOS3—systemic lupus erythematosus	2.15e-06	0.000109	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NOS3—systemic lupus erythematosus	2.1e-06	0.000106	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ALB—systemic lupus erythematosus	2.07e-06	0.000105	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ALB—systemic lupus erythematosus	2.05e-06	0.000104	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—EP300—systemic lupus erythematosus	2e-06	0.000101	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NOS3—systemic lupus erythematosus	1.98e-06	0.0001	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTGS2—systemic lupus erythematosus	1.97e-06	9.95e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NOS3—systemic lupus erythematosus	1.96e-06	9.92e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PPARG—systemic lupus erythematosus	1.95e-06	9.86e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTGS2—systemic lupus erythematosus	1.92e-06	9.72e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—EP300—systemic lupus erythematosus	1.84e-06	9.28e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTGS2—systemic lupus erythematosus	1.81e-06	9.16e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTGS2—systemic lupus erythematosus	1.8e-06	9.08e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ALB—systemic lupus erythematosus	1.76e-06	8.87e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NOS3—systemic lupus erythematosus	1.68e-06	8.48e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—EP300—systemic lupus erythematosus	1.64e-06	8.28e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—EP300—systemic lupus erythematosus	1.6e-06	8.08e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTGS2—systemic lupus erythematosus	1.54e-06	7.76e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—EP300—systemic lupus erythematosus	1.51e-06	7.61e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PPARG—systemic lupus erythematosus	1.51e-06	7.61e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—EP300—systemic lupus erythematosus	1.49e-06	7.55e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ALB—systemic lupus erythematosus	1.35e-06	6.84e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NOS3—systemic lupus erythematosus	1.3e-06	6.55e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—EP300—systemic lupus erythematosus	1.28e-06	6.45e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTGS2—systemic lupus erythematosus	1.18e-06	5.99e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—EP300—systemic lupus erythematosus	9.86e-07	4.98e-05	CbGpPWpGaD
